WO1996001263A1 - Procede de production d'un derive d'indolocarbazole - Google Patents
Procede de production d'un derive d'indolocarbazole Download PDFInfo
- Publication number
- WO1996001263A1 WO1996001263A1 PCT/JP1995/001309 JP9501309W WO9601263A1 WO 1996001263 A1 WO1996001263 A1 WO 1996001263A1 JP 9501309 W JP9501309 W JP 9501309W WO 9601263 A1 WO9601263 A1 WO 9601263A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- added
- mmo
- solvent
- reduced pressure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Definitions
- the present invention relates to a method for the selective and efficient industrial production of an indolobulbazole derivative having protein kinase C inhibitory activity.
- R 4 represents lower alkyl
- Compound (II) is known to have protein kinase C inhibitory activity, and its production method is disclosed in JP-A-62-155284 (upper formula). However, in this production method, the compound ( ⁇ ) is directly produced from the compound (I), and at the same time, the compound ( ⁇ ) in which the nitrogen atom of the amide group is lower alkylated and the compound ( ⁇ ) are produced. A large amount of the compound (IV) in which both the hydroxyl group and the nitrogen atom of the amide group are lower alkylated is by-produced, and the yield of the target compound ( ⁇ ) is low, which is unsuitable for mass production such as silica gel chromatography purification. A purification operation is required.
- the present invention provides a compound of the formula (V) wherein the nitrogen atom of the amide group of the compound (I) is selectively silylated.
- lower alkyl is straight-chain or branched having 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, It means tert-butyl, pentyl, isopentyl, neopentyl, hexyl, etc.
- aryl include phenyl and naphthyl.
- halogen means chlorine, bromine or iodine.
- the starting compound (I) is obtained by the method described in JP-A-60-41489. be able to.
- Compound (V) is obtained by combining compound (I) with 1 to 20 equivalents of a trisubstituted silyl chloride in the presence of 1 to 20 equivalents of a base such as triethylamine, pyridine or imidazole. 0 times the weight of halogenated hydrocarbons such as methylene chloride, chromate form, ethylene dichloride, carbon tetrachloride, etc., esters such as ethyl acetate, isopropyl acetate, tert-butyl acetate, isobutyl acetate, and butyl acetate, and dimethylformamide In a solvent such as solvent or a mixed solvent thereof at ⁇ 30 to 50 for 0.5 to 24 hours.
- a solvent such as solvent or a mixed solvent thereof at ⁇ 30 to 50 for 0.5 to 24 hours.
- Compound (VI) is obtained by combining compound (V) with 1 to 20 equivalents of an alkyl halide and 1 to 20 equivalents of a base such as lithium hydroxide, potassium hydroxide, sodium hydroxide, and sodium hydride.
- the reaction is carried out in a solvent such as dimethylformamide, dimethylsulfoxide, etc., which is 1 to 50 times the weight of the compound (V) or in a mixed solvent thereof at 130 to 50 ° C for 0.5 to 24 hours.
- a solvent such as dimethylformamide, dimethylsulfoxide, etc.
- Compound (II) can be prepared by converting compound (VI) into a solvent such as methanol, ethanol, isopropanol, or the like, acetone, acetone, or acetonitrile, or a mixed solvent thereof in an amount of 1 to 100 times the weight of compound (VI). It can be obtained by treating with 1 to 100 equivalents of hydrochloric acid, sulfuric acid, acetic acid, hydrobromic acid, trifluoroacetic acid, methanesulfonic acid and the like with a solvent. The reaction is carried out for 0.5 to 24 hours at a temperature ranging from 130 ° C. to the boiling point of the solvent used.
- a solvent such as methanol, ethanol, isopropanol, or the like, acetone, acetone, or acetonitrile, or a mixed solvent thereof in an amount of 1 to 100 times the weight of compound (VI). It can be obtained by treating with 1 to 100 equivalents of hydrochloric acid, sulfuric acid, acetic
- Intermediates and target compounds in the above-mentioned production methods are subjected to post-treatment methods commonly used in organic synthetic chemistry (for example, extraction, washing, drying, concentration, etc.), then crystallized and filtered, so that they can be simply obtained. It can be purified.
- the intermediate can be subjected to the next reaction as it is after the reaction or after the post-treatment without particular purification.
- the compound (II) thus obtained has a protein kinase C inhibitory activity.
- Example 1 9 ⁇ , 103,12 ⁇ _2- (tert-butyldimethylsilyl) — 2,3,9,10,11,12—Hexahydro 1 10—Hydroxy-1 9-Methyl-1-oxo-1,9-epoxy-1H-dindolo [1,2,3-fg: 3 ', 2,, 1,1-k1] Pyro mouth [3,4-i] [ 1, 6] benzodiazocin-10-carboxylic acid methyl ester [Compound (V-1)]
- Benzodizosine 10-carboxylic acid methyl ester [Compound (1)] 50.0 g (107 mmo 1) in 800 ml of ethyl acetate, 50 ml of dimethylformamide and 45.0 ml of triethylamine ( 32.1 mmo 1), and add 48.3 g (32 1 mmo 1) of tert-butyldimethylsilyl chloride to acetic acid at room temperature. A solution dissolved in 200 ml of ethyl acetate was added, and the mixture was stirred for 5 hours while maintaining the temperature at 25 to 35 ° C. To the reaction solution was added 100 ml of water, and the mixture was separated.
- the organic layer was washed twice with 100 ml of saturated saline and dried over anhydrous sodium sulfate. After the desiccant was filtered off and the solvent was distilled off under reduced pressure, 600 ml of methanol was added to the residue, followed by stirring at room temperature for 30 minutes. After adding 15 Oml of water and further stirring for 30 minutes, the mixture was stirred for 5 hours under ice cooling. The precipitated solid was collected by filtration and the solvent was distilled off under reduced pressure to give 51.7 g (89.0 mm 01, yield 83.2%) of the title compound.
- Example 2 9 ⁇ , 10 ⁇ , 12-II, 3,9,10,11,12-Hexahydride mouth 10-Hydroxy-1-9-methyl-11-oxo-1-2-triethyl Silyl 9, 1 2 1 Epoxy 1 1 ⁇ -Dindro [1, 2, 3-fg: 3,, 2,, ⁇ -k 1] Pyro mouth [3, 4-i] [1, 6] Benzodizosine 1 0-Methyl rubonic acid ester [Compound (V-2)]
- Example 3 9/10 / S, 12a—2,3,9,10,11,12—Hexahydro—10—Hydroxy-19-methyl-1-111-oxo1-2 — Triphenylenyl-1,9-epoxy-1-H-dindro [1,2,3-fg: 3,, 2,, ⁇ -k1] Pyro mouth [3,4-i] [1,6] benzodiazocin One 10-methyl ribonate [Compound (V-3)]
- Example 6 9,10 ⁇ , 12-1-2- (tert-butyldimethylsilyl) -12,3,9,10,11,12-hexahydro-10-methoxy-19-methyl 1-oxo-1 9,12-epoxy-1 H-dindolo [1,2,3-fg: 3 ', 2,, 1'-kl] Pyro mouth [3,4-i] [1,6] Benzodizosine-10-carboxylic acid methyl ester [Compound (VI-1)]
- VI-1) Compound (V-1) obtained in Example 1 was mixed with 50.0 g (86.1 mmo 1) of dimethylformamide in a nitrogen atmosphere at 100 m 0 1 And methyl iodide 16.5 m 1
- Example 7 9,10 ⁇ , 12 ⁇ -2,3,9,10,11,12-Hexahydrau 10-Methoxy-1-9-Methyl-1-oxo-1-2-Triethylsilyl 9,12-epoxy-1H-dindolo [1,2,3-fg: 3 ', 2', ⁇ -kl] Pyro-mouth [3,4-i] [1,6] benzodiazosin-1 0-force Rubonic acid methyl ester [Compound (VI-2)]
- the aqueous layer was extracted with 1 O ml of ethyl acetate, and the organic layers were combined, washed once with 10 ml of water, twice with 10 ml of saturated saline, and dried over anhydrous sodium sulfate. did.
- the drying agent is filtered off and the solvent is distilled off under reduced pressure.
- V-3) (VI-3)
- dimethylformamide and 0.13 of methyl iodide were added to 300 mg (0.43 mmmo 1) of the compound (V-3) obtained in Example 3.
- ml (2.07 mmo 1) was added, and at room temperature, 49 mg (2.07 mmo 1) of lithium hydroxide was added, and the mixture was stirred for 50 minutes while keeping at 20 to 30 ° C.
- the reaction solution was mixed with 7.5 ml of ethyl acetate, 6.0 m of water, cooled, mixed with 163 mg of citrate and 24 mg of sodium chloride, and separated.
- the aqueous layer was extracted with 5.0 ml of ethyl acetate, and the organic layers were combined, washed once with 5.0 ml of water, twice with 5.0 ml of saturated saline, and dried over anhydrous magnesium sulfate. .
- V-4) (VI-4) 15 Omg (0.24 Ommo 1) of the compound (V-4) obtained in Example 4 was added to dimethylformamide 3.Om 1 and Add methyl iodide 90 Z 1 (1.44 mmo 1), add lithium hydroxide 28 mg (1.16 mmo 1) under ice cooling, and keep at 0-5 ° C for 4.5 hours Stirred.
- the reaction mixture was added to a place where 1 Oml of ethyl acetate and 0.5 mM phosphate buffer (pH 5.9) were mixed and cooled, and the mixture was separated.
- the aqueous layer was extracted with 10 ml of ethyl acetate, and the organic layers were combined, washed once with 4.0 ml of water and then three times with 4.Oml of saturated saline, and dried over anhydrous magnesium sulfate.
- the selective and efficient industrial manufacturing method of the indolo carbazole derivative which has protein kinase C inhibitory activity can be provided.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69520554T DE69520554T2 (de) | 1994-07-04 | 1995-06-30 | Verfahren zur herstellung von indolocarbazol-derivaten |
US08/601,033 US5585488A (en) | 1994-07-04 | 1995-06-30 | Process for producing indolocarbazole derivatives |
EP95923556A EP0717045B1 (en) | 1994-07-04 | 1995-06-30 | Process for producing indolocarbazole derivative |
AT95923556T ATE200290T1 (de) | 1994-07-04 | 1995-06-30 | Verfahren zur herstellung von indolocarbazol- derivaten |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6/152103 | 1994-07-04 | ||
JP15210394 | 1994-07-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996001263A1 true WO1996001263A1 (fr) | 1996-01-18 |
Family
ID=15533125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/001309 WO1996001263A1 (fr) | 1994-07-04 | 1995-06-30 | Procede de production d'un derive d'indolocarbazole |
Country Status (7)
Country | Link |
---|---|
US (1) | US5585488A (ja) |
EP (1) | EP0717045B1 (ja) |
AT (1) | ATE200290T1 (ja) |
CA (1) | CA2170888A1 (ja) |
DE (1) | DE69520554T2 (ja) |
ES (1) | ES2157331T3 (ja) |
WO (1) | WO1996001263A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9540767B2 (en) | 2012-04-03 | 2017-01-10 | Kemira Oyj | Method for bleaching pulp |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69812177T2 (de) * | 1997-12-31 | 2004-01-15 | Cephalon Inc | 3'-epi k-252a derivate |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62155284A (ja) * | 1985-12-27 | 1987-07-10 | Kyowa Hakko Kogyo Co Ltd | 生理活性物質k−252の誘導体 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5013854A (en) * | 1989-02-02 | 1991-05-07 | Eli Lilly And Company | Process for preparing acid halides |
US5084568A (en) * | 1989-02-02 | 1992-01-28 | Eli Lilly And Company | Process for preparing acid halides |
ES2136103T3 (es) * | 1992-06-22 | 1999-11-16 | Kyowa Hakko Kogyo Kk | Procedimiento para la preparacion de derivados de estaurosporina. |
-
1995
- 1995-06-30 DE DE69520554T patent/DE69520554T2/de not_active Expired - Fee Related
- 1995-06-30 AT AT95923556T patent/ATE200290T1/de active
- 1995-06-30 US US08/601,033 patent/US5585488A/en not_active Expired - Fee Related
- 1995-06-30 WO PCT/JP1995/001309 patent/WO1996001263A1/ja active IP Right Grant
- 1995-06-30 EP EP95923556A patent/EP0717045B1/en not_active Expired - Lifetime
- 1995-06-30 CA CA002170888A patent/CA2170888A1/en not_active Abandoned
- 1995-06-30 ES ES95923556T patent/ES2157331T3/es not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62155284A (ja) * | 1985-12-27 | 1987-07-10 | Kyowa Hakko Kogyo Co Ltd | 生理活性物質k−252の誘導体 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9540767B2 (en) | 2012-04-03 | 2017-01-10 | Kemira Oyj | Method for bleaching pulp |
Also Published As
Publication number | Publication date |
---|---|
EP0717045A4 (en) | 1996-04-03 |
ES2157331T3 (es) | 2001-08-16 |
EP0717045A1 (en) | 1996-06-19 |
US5585488A (en) | 1996-12-17 |
EP0717045B1 (en) | 2001-04-04 |
DE69520554D1 (de) | 2001-05-10 |
DE69520554T2 (de) | 2001-08-23 |
ATE200290T1 (de) | 2001-04-15 |
CA2170888A1 (en) | 1996-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5202635B2 (ja) | インテグラーゼ阻害剤の調製のためのプロセスおよび中間体 | |
US9765088B2 (en) | Process for the preparation of rifamycin derivatives | |
JP6440896B2 (ja) | ベラプロストを作製するための方法 | |
JP2876712B2 (ja) | 光学活性ピラノベンゾオキサジアゾール誘導体 | |
US20050245750A1 (en) | Process for preparing 1,3-benzodioxole-2-spirocycloalkane derivative | |
WO1996001263A1 (fr) | Procede de production d'un derive d'indolocarbazole | |
JP2575781B2 (ja) | 2,3−ジアシルオキシ−4−ヒドロキシ−トペンタナールおよびその製造方法 | |
CN113164773A (zh) | 6-巯基嘌呤核苷类似物 | |
EP0308123B1 (en) | Crystalline antibiotic intermediate | |
WO1997043295A1 (fr) | Derives de d-pentofuranose et leur procede de preparation | |
US6426417B1 (en) | Processes and intermediates useful to make antifolates | |
JP3017338B2 (ja) | インドールアルカロイド誘導体製造用の新規中間体化合物 | |
JPH0940692A (ja) | グリシン誘導体の製造方法 | |
EP0186586A2 (en) | Cephem compounds and the production thereof | |
JP3727989B2 (ja) | インドール誘導体の製造法 | |
WO2023031960A1 (en) | Novel crystalline polymorph of lurbinectedin and improved process for the preparation of lurbinectedin | |
JP3857353B2 (ja) | ピロロキノリン誘導体 | |
JP4673313B2 (ja) | 1、2、3、9−テトラヒドロ−9−メチル−3−[(2−メチル−1h−イミダゾール−1−イル)メチル]−4h−カルバゾール−4−オンまたはその塩の製造方法 | |
JP3209679B2 (ja) | ジスルフィド化合物およびその製造法 | |
KR100402595B1 (ko) | 페니실린 g 페닐에스테르의 개량 제조 방법 | |
WO1994025021A1 (en) | Benzopyran derivative | |
JP2640622B2 (ja) | プログルメタシンの製造方法 | |
WO2007011021A1 (ja) | イミダゾチアゾール誘導体の製造方法 | |
WO2006068102A1 (ja) | 2-(ピラゾール-1-イル)ピリジン誘導体 | |
JPH06287197A (ja) | キラル1−β−メチルカルバペネム中間体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08601033 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2170888 Country of ref document: CA Ref document number: 1995923556 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1995923556 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995923556 Country of ref document: EP |